Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
The four-drug combination pill for HIV has significant sales potential, and will be a mainstay for Gilead to protect its leadership in the market, but with two novel components there is still much work to be done.
You may also be interested in...
With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate
Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class
Gilead's HIV Quad Pill Passes Tolerability Test, But Not With A Straight "A"
By and large, Gilead's latest Phase II results for its fixed-dose, four-drug "Quad" regimen for HIV and stand-alone data on its novel GS-9350 booster satisfied clinicians and analysts when it came to the commercially crucial tolerability test
With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate
Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class